CERPASS – A Study of Cemiplimab Given Alone Versus in Combination with the Oncolytic Immunotherapy RP1 to Treat Advanced Cutaneous Squamous Cell Carcinoma
‘*’ – The CERPASS study is currently active but not enrolling.
For more information about the CERPASS study, please see Clinical Trials.gov:
Clinical Trials.gov: https://clinicaltrials.gov/ct2/show/NCT04050436
This is a randomized Phase 2 clinical trial to compare the effects of cemiplimab alone versus a combination of cemiplimab and the investigational oncolytic immunotherapy RP1. Researchers will study the effectiveness of these treatments against tumors and how long the effect lasts for.